Nektar Therapeutics (NKTR) Financials
NKTR Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 398.0 million | 267.0 million |
2023-09-30 | 442.2 million | 282.9 million |
2023-06-30 | 494.3 million | 297.3 million |
2023-03-31 | 561.7 million | 320.9 million |
NKTR Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -47.3 million | 7.3 million |
2023-09-30 | -42.2 million | 8.1 million |
2023-06-30 | -51.7 million | 8.0 million |
2023-03-31 | -52.3 million | 10.0 million |
NKTR Net Income
No data available :(
NKTR Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 303.6 million | - | 117.8 million |
2023-09-30 | 372.7 million | - | 121.3 million |
2023-06-30 | 409.4 million | - | 124.8 million |
2023-03-31 | 456.8 million | - | 128.2 million |
NKTR Shares Outstanding
NKTR Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 237000 | 29.9 million | 17.3 million | - |
2023-09-30 | 33000 | 24.1 million | 21.1 million | - |
2023-06-30 | 162000 | 29.7 million | 17.9 million | - |
2023-03-31 | 433000 | 30.5 million | 21.1 million | - |
NKTR Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 23.9 million | 7.3 million |
2023-09-30 | 24.1 million | 12.4 million |
2023-06-30 | 20.5 million | 7.0 million |
2023-03-31 | 21.6 million | 7.1 million |
NKTR
Price: $1.50
52 week price:
Earnings Per Share: -1.45 USD
P/E Ratio: -0.38
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.8 million
Ebitda: 74.9 millionMarket Capitalization: 242.4 million